{"name":"Maze Therapeutics","slug":"maze-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":167500000,"revenueGrowth":0,"grossMargin":0,"rdSpend":108448000,"netIncome":-131120000,"cash":397127000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-29","type":"pipeline","source":"simplywall.st","summary":"Assessing Maze Therapeutics (MAZE) Valuation After Recent Share Price Weakness And Rich Price To Book Ratio - simplywall.st","headline":"Assessing Maze Therapeutics (MAZE) Valuation After Recent Share Price Weakness And Rich Price To Book Ratio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPX0dhdk50ZWl1dUVGdDE2QnRvalJTNHpSRU43UFRma1hHS2VkaE1LREJYb1dKblBNUjZWVi1CMUEzaFAtMlM2RFR1ZWhYQ3dVcElQbVNNYTZkLWdsZF9FU1RIcVV5b2w5Ml9pQ2RvSGU2ZHk2TlpWeGwwZF9EMnhQUG5GQjMzcDlNenQ3OGZ5SEpkREVGUzJ3RlRWODFVajYxdkxfaHpnek5NS193RDJBY25oTmJORk1ZMTVTaEtHUQ?oc=5","date":"2026-03-26","type":"pipeline","source":"Sahm","summary":"Maze Therapeutics Adds Pressure To Vertex In APOL1 Kidney Disease Race - Sahm","headline":"Maze Therapeutics Adds Pressure To Vertex In APOL1 Kidney Disease Race","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQUGFrWVd4TlV5WlZuOU9UUWhXZzF1QVBvcjhFRXpxXzhYcVIwNy1vZjVJb2c4alV5QlpQU3lzZFRabXdZc0xpZU9GVGJCM3Viems5bTd6SldNVkZKYkNRQXZZYzFIdEFlU2RUak9GenRKa0NsVlRnODF0QWxMdGx4NFBmSmhXRkI0ZkJ3UWlIcnRKMFZIVXNRcmlIWnp6eVhBSjJlZXBR?oc=5","date":"2026-03-25","type":"trial","source":"Investor's Business Daily","summary":"Why Maze Therapeutics Plunged 35% Despite 'Overwhelming Positive' Data - Investor's Business Daily","headline":"Why Maze Therapeutics Plunged 35% Despite 'Overwhelming Positive' Data - Investor's Business Daily","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOSFR0VFRRai1MU2dpejhZNTRZZ3d0QVFDS1FQYU9faGxTZ2FQZXcxV2VDYzBHZGsxVjVuUW1QZExMS2lXVVJuVUJRUzlOalV3R2FueWVsRHJfcS1hazVyaEl1TDdGX3h2ZXRoSEVvLVlvWk1majhURGVzUHYtM3JRaEZ0SVk0X3NoV19FVjJmakExQXp5bXVaYkx3?oc=5","date":"2026-03-25","type":"trial","source":"BioPharma Dive","summary":"Maze tumbles despite positive data for kidney disease drug - BioPharma Dive","headline":"Maze tumbles despite positive data for kidney disease drug","sentiment":"positive"},{"date":"2026-03-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOTW1XWUFnRF96a0RVaUtJS0hYWjhHN29Rdmp0aGduRXZYZW8tejdZSmhtY1BRdHlxZWExWGxfdWZFcUdvRGVVc2tJQl90cmZ4VnBtZGQxSlJsYWFYVllUR0tHaWhhSFA1X3hJakZXOExKb3pDcHduR2JKelMzSDVCWmpEWndhMjVZRVBqUW1waW9rNlA1cTMxYk50QUZzRnVUUTlHQ2FkS3NQMHc?oc=5","date":"2026-02-18","type":"trial","source":"Contract Pharma","summary":"Zifo Partners With Maze Therapeutics on Managing Biobank Data - Contract Pharma","headline":"Zifo Partners With Maze Therapeutics on Managing Biobank Data","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-28","type":"pipeline","source":"cnbc.com","summary":"Maze Therapeutics has jumped more than 80% in 3 months. Its CEO is bullish on what’s to come - cnbc.com","headline":"Maze Therapeutics has jumped more than 80% in 3 months. Its CEO is bullish on what’s to come","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPeHROVU1XMmlXdFI0ZTNaMlJxNVNyTmdUOWp4YmdJY0tUVHFGc01ZeXBPNzllOXRxeVFNalRuMnVEa2NwWWpZbVlDVDJvYWVpcUx5c3lWN19pcDJUTFowSzlUc3ctSHlMYjE5RkFjYUNfTlhaajlXdllHaHZkR25iV2xEazBzV04tMFF2Y2R3TjBkb2RlRnhxYkRXa3BoVm9GVmNWa1N2ZkRCWEFjMW5rSTRB?oc=5","date":"2025-09-14","type":"deal","source":"MedCity News","summary":"Maze Therapeutics Drug Shows Potential to Top Asset Acquired by Otsuka for $800M - MedCity News","headline":"Maze Therapeutics Drug Shows Potential to Top Asset Acquired by Otsuka for $800M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPYnVpNUFYelZqY2E1VHFHeTVvc25xVDcwWVhHX1Z5VjZaU0oxblpCX1poT25BaFFOamdrWXJSTUZ6dFJlMC1yMk0tejRlMkQ0Z3JrUUpEYjRBdTgyMjUzX1BBOUh4UzE2QjVaR2djSjBIek5RR1l6Ri1VQlByU3loWEFmMEFfTmJzeTNPTktsYm1PeXVrOGpDNUoyN0U?oc=5","date":"2025-09-12","type":"pipeline","source":"The Pharma Letter","summary":"$150 million private placement for Maze Therapeutics - The Pharma Letter","headline":"$150 million private placement for Maze Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE90UnBMdlVzR0RtQjViRzZyU3Y0SjRWb3BEQjFuSmtmenpDWnhaUERlckZGQ3Q0bm9iRUlhbnM0d1lsZDB0dlh6REMyekNxdW1YWUI4?oc=5","date":"2025-09-11","type":"trial","source":"FirstWord Pharma","summary":"Maze soars as early data back small molecule's potential in PKU, CKD - FirstWord Pharma","headline":"Maze soars as early data back small molecule's potential in PKU, CKD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPZjdyaUNqT19CamJOMUJfX0FwM00tdW5BRjBKMjdwRWdQb1JVemxTYmp2cjFHdVhwT0V4OHh2SDFtTXNCelVHVWxnWlNNTUxCa2duYlJqODh5NmNKalpGWUg3LXZ2Y0YyNS1JYjZIWkNRVFpaNTBNYTl2b2ViNGxWLUdyU2xscFlLZ0p2RENFT1RCbWVkZE9ManJ5aERzYmVaWEtpNy1MVXFhX2hXbEFYMG1iMXZVWmhDdVBXakR0U0trdw?oc=5","date":"2025-08-28","type":"pipeline","source":"Fierce Pharma","summary":"Maze Therapeutics referred to federal marketing regulators over challenge brought by Vertex - Fierce Pharma","headline":"Maze Therapeutics referred to federal marketing regulators over challenge brought by Vertex","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPMGdGVG41TTBKXzdGM052OUJVX2tXRGJyV21MSUw0ZEJKT0tIMzlvbnpRVlZUZ3ZvU2RiVmsyaGNaeWJsVlgtUnJ2UENDaWxVekI0cnhhdk5faFFoSFhzelFubmI3VEt2Mk5HT0N2ZUgzYUV2YWlEaUhsQzVpbmNObVp3UUszUlhxX2RDMklZeW5QMXMxZGRGSGkyN3RTR3BWeld2LW9oUzJGS3Y3cGc?oc=5","date":"2025-01-27","type":"trial","source":"Fierce Biotech","summary":"Maze rolls out map to $131M IPO, as phase 2 kidney disease trial readies for dosing - Fierce Biotech","headline":"Maze rolls out map to $131M IPO, as phase 2 kidney disease trial readies for dosing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQREo3UjF0aU15b2JRSDRUTmV0eklXaDdwNk0wMVIwSHhzWGtSaUxYNklMMnRveEFUZk9wR0lJeUJwaXRrZXBYa2F2eU5HamtpemNYanJncG56SWRCcFlvRzBFc2RvR3hHaGVvZHFydlJmQkQyRmRpSTk2ZEZOaHhHa3paejJnWm1JTGdHejJtUW5DdzZ0bFROaDVkaEVfSEtOang2NVFRNzJiMEhla05CNUhHM0ZCdkw1WG41TG1B?oc=5","date":"2025-01-27","type":"pipeline","source":"Reuters","summary":"Drug developer Maze Therapeutics eyes up to $728 million valuation in US IPO - Reuters","headline":"Drug developer Maze Therapeutics eyes up to $728 million valuation in US IPO","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":167500000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":167500000,"period":"2024-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":108448000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-131120000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":397127000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}